These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18664161)

  • 1. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo.
    Fernandez-Obregon AC
    J Drugs Dermatol; 2008 Jul; 7(7):679-81. PubMed ID: 18664161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A patient with psoriasis and vitiligo treated with etanercept.
    Campanati A; Giuliodori K; Ganzetti G; Liberati G; Offidani AM
    Am J Clin Dermatol; 2010; 11 Suppl 1():46-8. PubMed ID: 20586509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repigmentation of vitiligo during efalizumab.
    Wakkee M; Assen YJ; Thio HB; Neumann HA
    J Am Acad Dermatol; 2008 Aug; 59(2 Suppl 1):S57-8. PubMed ID: 18625392
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA; Miller B; Gordon KB; Caro I; Kwon P; Compton PG; Leonardi CL;
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
    Leonardi C; Menter A; Hamilton T; Caro I; Xing B; Gottlieb AB
    Br J Dermatol; 2008 May; 158(5):1107-16. PubMed ID: 18373710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case reports: practical experience with efalizumab in hand and foot psoriasis.
    Cohen DJ; Scherschun L
    J Drugs Dermatol; 2007 Dec; 6(12):1224-30. PubMed ID: 18189064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab: a biological agent for the treatment of psoriasis.
    Hodulik S; Hadi S
    Rev Recent Clin Trials; 2006 May; 1(2):165-8. PubMed ID: 18473968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efalizumab.
    Talamonti M; Spallone G; Di Stefani A; Costanzo A; Chimenti S
    Expert Opin Drug Saf; 2011 Mar; 10(2):239-51. PubMed ID: 21214420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
    Lowes MA; Turton JA; Krueger JG; Barnetson RS
    BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA; Driessen RJ; Langewouters AM; Boezeman JB; Van De Kerkhof PC; De Jong EM
    J Dermatolog Treat; 2007; 18(2):76-83. PubMed ID: 17520463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study.
    Gisondi P; Giglio MD; Girolomoni G
    J Dermatolog Treat; 2006; 17(3):172-5. PubMed ID: 16854760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.